{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:41:34Z","timestamp":1789062094215,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hinova Pharmaceuticals Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>HP501 is a highly selective renal urate transporter 1 (URAT1) inhibitor used for treating hyperuricemia. This study aimed to evaluate the tolerability, pharmacokinetics, and pharmacodynamics of HP501 in male Chinese patients. Patients with hyperuricemia were sequentially assigned to receive oral doses of HP501 (30, 50, 60, 90, and 120\u00a0mg) as a single dose on Day 1 and as once-daily doses from Days 4 to 13. Safety, pharmacokinetic, and pharmacodynamic data were collected. Multiple oral doses of HP501 were well-tolerated in all the cohorts. The most common adverse events (\u2265\u200910% of patients) of any grade regardless of drug relationship were gout flare (14 patients, 25.93%), diarrhea (12 patients, 22.22%), elevated ALT (8 patients, 14.81%), hypertriglyceridemia (7 patients, 12.96%), dry mouth (7 patients, 12.96%) and oral ulcer (7 patients, 12.96%). All adverse events were mild or moderate. The C<jats:sub>max<\/jats:sub> and exposure (AUC) of HP501 was approximately dose-proportional between 30 and 120\u00a0mg. A dose-dependent serum uric acid (UA)-lowering effect was observed in the dose range of 30 to 60\u00a0mg and the serum UA lowering effect was similar between 90 and 120\u00a0mg on day 13, indicating that the maximal serum UA lowering effect of HP501 was achieved at 90\u00a0mg in the patients with hyperuricemia. In conclusion, the tolerability, pharmacokinetics, and pharmacodynamics supported 90\u00a0mg HP501 for subsequent clinical studies of this highly selective URAT1 inhibitor.<\/jats:p><jats:p>Clinical Trial registration: No. CTR20212259 (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chinadrugtrials.org.cn\/\">http:\/\/www.chinadrugtrials.org.cn\/<\/jats:ext-link>) was registered in September 2021, and No. CTR20222257 was registered in September 2022.<\/jats:p>","DOI":"10.1038\/s41598-023-49052-x","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T04:22:54Z","timestamp":1702527774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A dose-escalation study of HP501, a highly selective URAT1 inhibitor, in male Chinese patients with hyperuricemia"],"prefix":"10.1038","volume":"13","author":[{"given":"Ruilin","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longxia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengqiong","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,14]]},"reference":[{"issue":"7","key":"49052_CR1","first-page":"3167","volume":"12","author":"L Li","year":"2020","unstructured":"Li, L., Zhang, Y. & Zeng, C. Update on the epidemiology, genetics, and therapeutic options of hyperuricemia. Am. J. Transl. Res. 12(7), 3167\u20133181 (2020).","journal-title":"Am. J. Transl. Res."},{"issue":"2","key":"49052_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41584-019-0334-3","volume":"16","author":"LAB Joosten","year":"2020","unstructured":"Joosten, L. A. B., Cri\u015fan, T. O., Bjornstad, P. & Johnson, R. J. Asymptomatic hyperuricaemia: A silent activator of the innate immune system. Nat. Rev. Rheumatol. 16(2), 75\u201386. https:\/\/doi.org\/10.1038\/s41584-019-0334-3 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"49052_CR3","doi-asserted-by":"publisher","first-page":"791983","DOI":"10.3389\/fimmu.2021.791983","volume":"12","author":"M Zhang","year":"2021","unstructured":"Zhang, M. et al. Prevalence of hyperuricemia among chinese adults: Findings from two nationally representative cross-sectional surveys in 2015\u201316 and 2018\u201319. Front. Immunol. 12, 791983. https:\/\/doi.org\/10.3389\/fimmu.2021.791983 (2021).","journal-title":"Front. Immunol."},{"issue":"11","key":"49052_CR4","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","volume":"11","author":"CF Kuo","year":"2015","unstructured":"Kuo, C. F., Grainge, M. J., Zhang, W. & Doherty, M. Global epidemiology of gout: Prevalence, incidence and risk factors. Nat. Rev. Rheumatol. 11(11), 649\u2013662. https:\/\/doi.org\/10.1038\/nrrheum.2015.91 (2015).","journal-title":"Nat. Rev. Rheumatol."},{"issue":"11","key":"49052_CR5","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.3390\/ijms21114066","volume":"21","author":"M Gaubert","year":"2020","unstructured":"Gaubert, M. et al. Hyperuricemia and hypertension, coronary artery disease, kidney disease: From concept to practice. Int. J. Mol. Sci. 21(11), 4066. https:\/\/doi.org\/10.3390\/ijms21114066 (2020).","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"49052_CR6","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1002\/art.41008","volume":"71","author":"AB Vargas-Santos","year":"2019","unstructured":"Vargas-Santos, A. B., Neogi, T., da Rocha, C.-P., Kapetanovic, M. C. & Turkiewicz, A. Cause-specific mortality in gout: Novel findings of elevated risk of non-cardiovascular-related deaths. Arthritis Rheumatol. 71(11), 1935\u20131942. https:\/\/doi.org\/10.1002\/art.41008 (2019).","journal-title":"Arthritis Rheumatol."},{"issue":"11","key":"49052_CR7","doi-asserted-by":"publisher","first-page":"5089","DOI":"10.1093\/rheumatology\/keab198","volume":"60","author":"Y Lin","year":"2021","unstructured":"Lin, Y. et al. Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: A randomized controlled phase II study. Rheumatology (Oxford) 60(11), 5089\u20135097. https:\/\/doi.org\/10.1093\/rheumatology\/keab198 (2021).","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"49052_CR8","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1080\/13543776.2022.2165911","volume":"32","author":"X Shi","year":"2022","unstructured":"Shi, X. et al. Novel urate transporter 1 (URAT1) inhibitors: A review of recent patent literature (2020-present). Expert Opin. Ther. Pat. 32(12), 1175\u20131184. https:\/\/doi.org\/10.1080\/13543776.2022.2165911 (2022).","journal-title":"Expert Opin. Ther. Pat."},{"issue":"7","key":"49052_CR9","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","volume":"16","author":"M Dehlin","year":"2020","unstructured":"Dehlin, M., Jacobsson, L. & Roddy, E. Global epidemiology of gout: Prevalence, incidence, treatment patterns and risk factors. Nat. Rev. Rheumatol. 16(7), 380\u2013390. https:\/\/doi.org\/10.1038\/s41584-020-0441-1 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"issue":"1217","key":"49052_CR10","first-page":"U1528","volume":"118","author":"S Kumar","year":"2005","unstructured":"Kumar, S., Ng, J. & Gow, P. Benzbromarone therapy in management of refractory gout. New Zealand Med. J. 118(1217), U1528 (2005).","journal-title":"New Zealand Med. J."},{"issue":"12","key":"49052_CR11","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1093\/rheumatology\/kex350","volume":"56","author":"AK Tausche","year":"2017","unstructured":"Tausche, A. K. et al. Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: A 6 month phase 3 clinical trial and extension study. Rheumatology (Oxford) 56(12), 2170\u20132178. https:\/\/doi.org\/10.1093\/rheumatology\/kex350 (2017).","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"49052_CR12","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1210\/clinem\/dgac032","volume":"107","author":"Z Wang","year":"2022","unstructured":"Wang, Z. et al. Safety, efficacy, and pharmacokinetics of HP501 in healthy volunteers and hyperuricemic patients: A phase I\/IIa study. J. Clin. Endocrinol. Metab. 107(6), 1667\u20131678. https:\/\/doi.org\/10.1210\/clinem\/dgac032 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"49052_CR13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3760\/cma.j.issn.0578-1426.2017.03.021","volume":"56","author":"L Li","year":"2017","unstructured":"Li, L., Zhu, X. & Dai, Y. Chinese multi-disciplinary consensus on the diagnosis and treatment of hyperuricemia and its related diseases. Zhonghua Nei Ke Za Zhi 56(3), 235\u2013248. https:\/\/doi.org\/10.3760\/cma.j.issn.0578-1426.2017.03.021 (2017).","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"10","key":"49052_CR14","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1023\/a:1026451721686","volume":"17","author":"BP Smith","year":"2000","unstructured":"Smith, B. P. et al. Confidence interval criteria for assessment of dose proportionality. Pharm. Res. 17(10), 1278\u20131283. https:\/\/doi.org\/10.1023\/a:1026451721686 (2000).","journal-title":"Pharm. Res."},{"issue":"1","key":"49052_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s42358-019-0080-x","volume":"59","author":"VF Azevedo","year":"2019","unstructured":"Azevedo, V. F., Kos, I. A., Vargas-Santos, A. B., da Rocha Castelar Pinheiro, G. & Dos Santos Paiva, E. Benzbromarone in the treatment of gout. Adv. Rheumatol. 59(1), 37. https:\/\/doi.org\/10.1186\/s42358-019-0080-x (2019).","journal-title":"Adv. Rheumatol."},{"issue":"6","key":"49052_CR16","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40261-023-01274-7","volume":"43","author":"R Ding","year":"2023","unstructured":"Ding, R. et al. A phase I study to evaluate the pharmacokinetic drug-drug interaction of HP501, febuxostat, and colchicine in male Chinese patients with hyperuricemia. Clin. Drug. Investig. 43(6), 401\u2013411. https:\/\/doi.org\/10.1007\/s40261-023-01274-7 (2023).","journal-title":"Clin. Drug. Investig."},{"issue":"5","key":"49052_CR17","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/ckj\/sfx036","volume":"10","author":"MD Sanchez-Ni\u00f1o","year":"2017","unstructured":"Sanchez-Ni\u00f1o, M. D. et al. Lesinurad: What the nephrologist should know. Clin. Kidney J. 10(5), 679\u2013687. https:\/\/doi.org\/10.1093\/ckj\/sfx036 (2017).","journal-title":"Clin. Kidney J."},{"issue":"1","key":"49052_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/rheumatology\/key245","volume":"58","author":"R Terkeltaub","year":"2019","unstructured":"Terkeltaub, R. et al. Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout. Rheumatology (Oxford) 58(1), 61\u201369. https:\/\/doi.org\/10.1093\/rheumatology\/key245 (2019).","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"49052_CR19","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1002\/art.40159","volume":"69","author":"N Dalbeth","year":"2017","unstructured":"Dalbeth, N. et al. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: Findings of a phase III clinical trial. Arthritis Rheumatol. 69(9), 1903\u20131913. https:\/\/doi.org\/10.1002\/art.40159 (2017).","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"49052_CR20","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1080\/14397595.2018.1538003","volume":"29","author":"D Fitz-Patrick","year":"2019","unstructured":"Fitz-Patrick, D. et al. Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and\/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials. Mod. Rheumatol. 29(6), 1042\u20131052. https:\/\/doi.org\/10.1080\/14397595.2018.1538003 (2019).","journal-title":"Mod. Rheumatol."},{"issue":"11","key":"49052_CR21","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1080\/14656566.2021.1918102","volume":"22","author":"T Ishikawa","year":"2021","unstructured":"Ishikawa, T., Takahashi, T., Taniguchi, T. & Hosoya, T. Dotinurad: A novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout. Expert Opin. Pharmacother. 22(11), 1397\u20131406. https:\/\/doi.org\/10.1080\/14656566.2021.1918102 (2021).","journal-title":"Expert Opin. Pharmacother."},{"issue":"4","key":"49052_CR22","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/1756-185x.13266","volume":"21","author":"KH Yu","year":"2018","unstructured":"Yu, K. H. et al. Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan. Int. J. Rheum. Dis. 21(4), 772\u2013787. https:\/\/doi.org\/10.1111\/1756-185x.13266 (2018).","journal-title":"Int. J. Rheum. Dis."},{"issue":"1","key":"49052_CR23","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1038\/s41598-018-22570-9","volume":"8","author":"P Song","year":"2018","unstructured":"Song, P. et al. Prevalence and correlates of hyperuricemia in the middle-aged and older adults in China. Sci. Rep. 8(1), 4314. https:\/\/doi.org\/10.1038\/s41598-018-22570-9 (2018).","journal-title":"Sci. Rep."},{"key":"49052_CR24","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.2147\/jir.s284759","volume":"15","author":"AV Patel","year":"2022","unstructured":"Patel, A. V. & Gaffo, A. L. Managing gout in women: Current perspectives. J. Inflamm. Res. 15, 1591\u20131598. https:\/\/doi.org\/10.2147\/jir.s284759 (2022).","journal-title":"J. Inflamm. Res."},{"issue":"10264","key":"49052_CR25","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/s0140-6736(20)32234-0","volume":"396","author":"IS Mackenzie","year":"2020","unstructured":"Mackenzie, I. S. et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): A multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet 396(10264), 1745\u20131757. https:\/\/doi.org\/10.1016\/s0140-6736(20)32234-0 (2020).","journal-title":"Lancet"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-49052-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-49052-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-49052-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T04:24:51Z","timestamp":1702527891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-49052-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,14]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["49052"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-49052-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,14]]},"assertion":[{"value":"17 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Xinghai Li and Yi Zhou are employees of Hinova Pharmaceuticals Inc. The other authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22190"}}